DUBLIN, June 5, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that post-hoc data from two Phase 3 studies of XIAFLEX ® (collagenase clostridium histolyticum, or CCH, ...
The Food and Drug Administration (FDA) has approved Xiaflex as the first non-surgical treatment for Peyronie’s disease (PD), a condition that causes penis curvature that can make sexual intercourse ...
DUBLIN, Oct. 22, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that new post-hoc data from two Phase 3 studies of XIAFLEX ® (collagenase clostridium histolyticum, or CCH) in ...
A baseline analysis from IMPRESS focuses on the psychosocial impact on men with PD, specifically the level of PD bother and distress associated with PD as related to the degree of penile curvature ...
XIAFLEX (collagenase clostridium histolyticum) 0.5mg for injection Auxilium Pharmaceuticals announced new data from its Phase 3 IMPRESS trials that evaluated Xiaflex for the treatment of Peyronie's ...
Endo is ramping up the next phase of its Dupuytren's contracture marketing drive. Not long after running its first branded ad for Xiaflex in the indication, the drugmaker has dubbed September the ...
DUBLIN, Oct. 22, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that new post-hoc data from two Phase 3 studies of XIAFLEX ® (collagenase clostridium histolyticum, or CCH) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback